Global AI In Pharmacovigilance Market Strategic Research Report

The global AI in pharmacovigilance market has emerged as one of the most commercially consequential intersections of artificial intelligence and life sciences regulation. Valued at approximately USD 1.8 billion in 2024, the market encompasses AI-powered solutions applied to adverse event detection, signal detection and management, case processing automation, regulatory submission support, and post-market surveillance. As pharmaceutical pipelines expand and drug safety obligations intensify under the watch of agencies such as the FDA, EMA, and PMDA, the imperative for scalable, intelligent pharmacovigilance infrastructure has never been more pronounced. The market's significance extends beyond operational efficiency — AI-driven pharmacovigilance is increasingly treated as a strategic risk management capability by both originator pharmaceutical companies and contract research organizations managing complex global safety databases.

Three primary forces are accelerating adoption across this market. First, the exponential growth in unstructured adverse event data from electronic health records, social media platforms, and patient-reported outcomes has rendered manual case processing commercially unviable at scale; natural language processing models can now extract, classify, and route Individual Case Safety Reports at throughput rates estimated to be four to six times faster than human reviewers. Second, regulatory agencies in the United States, European Union, and Japan are actively publishing guidance on the use of AI in drug safety monitoring, reducing the compliance ambiguity that historically deferred enterprise investment decisions. Third, the maturation of cloud-native safety platforms offered on subscription models has lowered the capital barriers for mid-tier specialty pharma and biotech firms. Against these tailwinds, data privacy regulation — particularly the EU's GDPR and its interaction with cross-border patient data flows — continues to constrain the design of centralized AI training pipelines and creates material compliance costs for multinational deployments.

This report provides a comprehensive assessment of the global AI in pharmacovigilance market across the 2025–2032 forecast period, with a 2024 base year. It covers market segmentation by technology type, application, and end-user vertical; regional and country-level demand analysis; competitive profiling of ten major vendors; and analysis of the regulatory, technological, and strategic forces shaping the competitive landscape. The report is designed for corporate strategy teams evaluating build-versus-buy decisions, investment analysts benchmarking vendor performance, M&A advisors assessing acquisition targets, and procurement managers selecting enterprise safety platforms.